Portfolio company
Skyhawk Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops small molecules that modulate RNA for patients with rare neurological, oncological, and autoimmune diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Remix Therapeutics
This biotechnology company develops small molecule therapies that modulate RNA processing to treat cancers and genetic diseases for patients with unmet medical needs.
Shape Therapeutics
The company develops programmable RNA medicines and delivery systems for patients with genetic disorders and other hard-to-treat diseases.
Scenic Biotech
This company develops disease-modifying small molecule therapeutics for patients with rare genetic and neurodegenerative disorders using its proprietary genetic modifier discovery platform.
Ribonaut Therapeutics
Ribonaut Therapeutics develops small molecule drugs that target and degrade disease-causing RNA to treat neurological conditions and movement disorders for human patients.
Typewriter Therapeutics
The company develops RNA-based genetic medicines for patients with cancer, autoimmune conditions and rare genetic diseases.
Arrakis Therapeutics
This biopharmaceutical company develops oral, small-molecule medicines that target RNA to treat patients with cancer, cardiovascular conditions, neurodegeneration and rare genetic diseases.
Orb Therapeutics
This company develops programmable RNA therapeutics and computational platforms to treat patients with genetic and neurological diseases.
Ribometrix
The company develops small molecule therapeutics targeting RNA structures to treat human diseases for pharmaceutical partners and patients with cancer or neurodegenerative conditions.